Search

BMN-351

BMN-351 is a fully modified 18-mer oligonucleotide with a TEG modification at its 5' end that binds to exon 51 of dystrophin pre-mRNA. … It is under investigation for the treatment of Duchenne Muscular Dystrophy (DMD).

WX-UK1

Independent studies show that administration of Wx-UK1 resulted in a decrease of tumor cell invasion, suggesting its efficacy as a an adjuvant antimetastatic therapy of carcinomas. … a key role in metastasis and primary tumor growth of breast, gastric, colon cancer, and various other solid tumors.

Shark liver oil

The potential benefit of shark oil has been experimented in different therapeutic implications, where it is claimed to improve immune responses and exert an antitumor activity. … Shark oil is a rich source of alkylglycerols and squalene, with relatively low amounts of n-3 polyunsaturated fatty acids.

Chlormadinone

OXI-4503

to an orthoquinone chemical species that has direct cytotoxic effects on tumor cells. … OXI-4503 is investigated in clinical trials for treating cancer/tumors. OXI-4503 is a solid. OXI-4503 blocks and destroys tumor vasculature, resulting in extensive tumor cell death and necrosis.

EW-A-401

EW-A-401 is a circle of genetic material (plasmid DNA) that instructs the body to produce a genetically-engineered transcription factor, a protein that regulates expression of genes. … This specific transcription factor has been shown in animal studies to increase expression of the VEGF-A gene, and to promote the growth of new blood vessels.

NP-50301

It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. … NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals.

Meningococcal polysaccharide vaccine group Y

It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup Y. … *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia.

Inbakicept

It is one of the active ingredients in Anktiva, a combination product also containing [nogapendekin alfa], where a single inbakicept is complexed with two nogapendekin alfa components. … [A263617, A263622] Inbakicept, in combination with nogapendekin alfa, mimics the actions of IL-15, stimulating the activation and proliferation of natural killer cells and CD8+ memory T cells, which also

AT9283

AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer. … It was discovered and developed internally using Astex’s fragment-based drug discovery platform, Pyramid.